Kawasaki disease is a vasculitis syndrome that occurs in children. There are currently effective clinical treatments for this disease, which are relatively curable; however, in the case of refractory Kawasaki disease, the development of cardiovascular complications often makes treatment more difficult. The disease is often treated with intravenous immunoglobulin and oral aspirin, especially within the first 7-10 days of illness. If persistent or recurrent fever persists after treatment, refractory Kawasaki disease should be alerted to the increased likelihood of cardiovascular complications, and glucocorticosteroids (prednisolone) or cyclosporine should be added to the treatment. The difficulty in treating this disease is the management and prevention of concomitant cardiovascular disease. Patients should be closely monitored for coronary artery involvement within 2 weeks of treatment, and any abnormalities should be treated as soon as possible.